ライフサイエンスコーパス: cysteamine

1 captopropionic acid, 2-mercapto ethanol, and cysteamine).

2 iers such as SIGCAFKILGY(-cysteamine) [SIGC(-cysteamine)].

3 to produce pantothenic acid (vitamin B5) and cysteamine.

4 increased the production of hypotaurine from cysteamine.

5 backbone derived from HCN and branches from cysteamine.

6 mines which can be driven by ADO's substrate cysteamine.

7 o biologically relevant thiols: cysteine and cysteamine.

8 pionic acid, 4-pyridinylethanemercaptan, and cysteamine.

9 caftor and/or the alternative CFTR modulator cysteamine.

10 Conventional cysteamine (0.1% to 0.3%) performed better than placebo

11 terms of decreasing corneal cystine density, cysteamine (0.55%) was better than cystamine (0.55%), an

12 tify a thiol oxidase, previously assigned as cysteamine (2-aminoethanethiol) dioxygenase (ADO), as a

13 o the enzymes cysteine dioxygenase (CDO) and cysteamine (2-aminoethanethiol) dioxygenase (ADO).

14 rystals, P21/n space group) using zwitterion cysteamine (2-aminoethanethiol) linker, and its remarkab

15 -cysteine with isosteric substrate analogues cysteamine, 3-mercaptopropionic acid, and propane thiol

16 Fresh cysteamine (600 mg/kg) was added to drinking water daily

17 During these years, cysteamine, a cystine-depleting agent, was introduced fo

18 pered our understanding of the metabolism of cysteamine, a product of the constitutive degradation of

19 pporting this model, maternal treatment with cysteamine-a lysosome-penetrant thiol-rescued the develo

20 ation and ligation with molecules containing cysteamine, analogous to native chemical ligation of thi

21 DO) is a thiol dioxygenase that sulfinylates cysteamine and amino-terminal cysteines in polypeptides.

22 herapy with a cystine-depleting drug such as cysteamine and an mTOR pathway inhibitor such as everoli

23 Two types of cationic AuNPs, cysteamine and CTAB capped, were compared to achieve max

24 Cysteamine and cystamine also augmented basal intracellu

25 of cystinotic iPSCs or kidney organoids with cysteamine and everolimus corrects all of the observed p

26 ioprotectants including human serum albumin, cysteamine and glycerol were evaluated.

27 However, experimental studies with the thiol cysteamine and its disulfide cystamine have demonstrated

28 near growth was associated with early use of cysteamine and lower leukocyte cystine levels.

29 ostasis in humans by oxidizing the sulfur of cysteamine and N-terminal cysteine-containing proteins t

30 nol formation, while mixed SAMs with varying cysteamine and propanethiol ratios allow for precise tun

31 e or withanolide A, was highly reactive with cysteamine and rapidly succumbed to irreversible nucleop

32 ctroscopies, we explored the binding mode of cysteamine and RGS5 to human and mouse ADO proteins in t

33 therefore studied the actions of cystamine, cysteamine and several reference thiol agents as cytopro

34 ences in reactivity of thiocyanurates toward cysteamines and thiols has been explained based on conce

35 ell-known radioprotective agents L-cysteine, cysteamine, and 2-[(aminopropyl)amino]ethanethiol (WR-10

36 was further prepared by gold nanoparticles, cysteamine, and glutaraldehyde in turn.

37 Intracellular thiols (e.g., cysteine, cysteamine, and glutathione) can trigger the release of

38 enal transplantation, administration of oral cysteamine, and time and cause of death.

39 Compared to placebo and control, the cysteamine arm was better in terms of improvements and r

40 Our NMR studies confirm cysteamine as an efficient and selective HCHO scavenger

41 SPME-GC-MS-based HCHO detection method using cysteamine as an HCHO scavenger.

42 t assay using 14C-(C-1)-labeled L-serine and cysteamine as substrates, counting the thialysine produc

43 Patients received oral cysteamine bitartrate (60 mg/kg per day) and N-acetylcys

44 ndings suggest that combination therapy with cysteamine bitartrate and N-acetylcysteine is associated

45 aimed to assess whether combination of oral cysteamine bitartrate and N-acetylcysteine is beneficial

46 is required to determine safe and effective cysteamine bitartrate concentrations to further evaluate

47 Regarding liver transaminases, Cysteamine Bitartrate Delayed Release (CBDR) most effect

48 olled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the

49 d liver histology using data from the CyNCh (Cysteamine Bitartrate Delayed-Release for the Treatment

50 Mechanistic profiling of cysteamine bitartrate effects showed it increases aspart

51 At 10 to 100 mum concentrations, cysteamine bitartrate improved multiple RC complex disea

52 cally evaluated the therapeutic potential of cysteamine bitartrate in RC disease models spanning thre

53 Cysteamine bitartrate is a US Food and Drug Administrati

54 Overall, these data suggest cysteamine bitartrate may hold therapeutic potential in

55 th glutathione deficiency and ameliorated by cysteamine bitartrate or N-acetylcysteine therapy.

56 tic treatment of surf1-/- larvae with either cysteamine bitartrate or N-acetylcysteine, but not other

57 Mechanistic analyses demonstrated cysteamine bitartrate pretreatment did not improve compl

58 Micromolar range cysteamine bitartrate treatment in Caenorhabditis elegan

59 two patients, which disappeared when liquid cysteamine bitartrate was replaced with capsules.

60 s, we evaluated the antifibrotic efficacy of cysteamine bitartrate, an antioxidant therapy for patien

61 emonstrated the narrow therapeutic window of cysteamine bitartrate, with toxicity at millimolar level

62 ologues with O(2) - as in case of the parent cysteamine-bound complexes - the dioxygenation of the ch

63 Further investigation of the cysteamine-bound or a peptide mimic of N-terminus RGS5 b

64 e vanin-1 produces pantothenic acid (PA) and cysteamine, but the role of the vanin-1 /PA axis in meta

65 the sensitive voltammetric determination of cysteamine (CA), nicotinamide adenine dinucleotide (NADH

66 such as acetone, acetaldehyde, isoprene, or cysteamine can be detected in the breath gas with SPI, R

67 The large difference in the yields of cysteamine can be used to explain the drugs' different t

68 sulfonic acid, mercapto-propionyglycine, and cysteamine can directly sequester aldehydes.

69 The sensor relies on cysteamine capped gold nanoparticles (N-AuNPs) covalentl

70 Additionally, we utilized cysteamine capped gold-nanoparticles (Cyst-AuNPs) to aug

71 e for MC-LR biosensing with anti-MC-LR/MC-LR/cysteamine-coating.

72 protection using a recently developed Trolox-cysteamine cocktail.

73 of autophagy activators involving fatty acid cysteamine conjugates.

74 Lipophilic thiols such as mercaptoethanol or cysteamine could partially reverse the CCl4-induced calc

75 By functionalizing cysteamine (CS)-stabilized gold nanoparticles (CS-AuNPs)

76 , separation-free and selective detection of cysteamine (CSH).

77 Copper Cysteamine (Cu-Cy) is a new photosensitizer and a novel

78 yer principle by modifying Au electrode with cysteamine (Cys) and immobilization of ferrocene cored p

79 lized on the Au/SPE previously aminated with cysteamine (Cys) by self-assembling monolayer technique.

80 In electrode fabrication cysteamine (Cys) was the first agent covalently linked o

81 The zwitterionic organosulfide, cysteamine (CYS; (+)NH(3)(CH(2))(2)S(-)), serves as both

82 newer formulation, the standard formulation (cysteamine [Cystaran]; 0.55% cysteamine hydrochloride +

83 nic acid (cysteine without the amino group), cysteamine (cysteine without the carboxylic acid), or me

84 The reaction was highly specific for cysteamine; cysteine was not oxidized by the enzyme, and

85 Current therapy with cysteamine delays but does not prevent kidney failure an

86 In the case of cysteamine derivatives, a broader antibacterial activity

87 Decrease of lysosomal cystine levels by cysteamine did not rescue mTORC1 activation in these cel

88 raldehyde crosslinking and functionalized by cysteamine dihydrochloride.

89 Cysteamine dioxygenase (ADO) has been reported to exhibi

90 Cysteamine dioxygenase (ADO) plays a vital role in regul

91 etal-substituted catalytic activity of human cysteamine dioxygenase (ADO), an enzyme pivotal in regul

92 combinant protein, ADO exhibited significant cysteamine dioxygenase activity in vitro.

93 ggest that ADO is responsible for endogenous cysteamine dioxygenase activity.

94 ly of enzymes includes cysteine dioxygenase, cysteamine dioxygenase, mercaptosuccinate dioxygenase, a

95 he protein, relatively little is known about cysteamine dioxygenase.

96 ependent dioxygenase 2-aminoethanethiol (aka cysteamine) dioxygenase (ADO) has recently been identifi

97 ned carbon chain and lacks a carboxyl group, cysteamine displays a catalytic efficiency (kcat/Km) wit

98 However, because cysteamine does not correct all complications of cystino

99 nolayers including mercaptobenzimidazole and cysteamine films, showcasing the potential for tailoring

100 modified with a self-assembled monolayer of cysteamine followed by cross-linking with glutaraldehyde

101 ations and deaths than patients who received cysteamine for fewer than 8 years.

102 to be ineffective at zinc ejection, although cysteamine formed a transient complex with the zinc fing

103 d that the steady state percentage yields of cysteamine from cystamine and pantethine during the tran

104 vate, homocysteine (from cystathionine), and cysteamine (from S-aminoethyl-L-cysteine).

105 In the case of the bacterial member ELIC, a cysteamine-gated channel from Erwinia chrisanthemi, a st

106 abeled diketide-SNAC 2 and N-[1-(14)C-acetyl]cysteamine gave a k(exch) of 0.15 +/- 0.06 min(-)(1), wi

107 We report herein the use of cysteamine-graphene oxide modified gold microelectrode a

108 amine) specifically and efficiently leads to cysteamine (half-cystamine) modification of a single sit

109 ted the extracellular levels of free reduced cysteamine, homocysteine, and cysteine from OHSCs within

110 Concentrations of cysteamine, homocysteine, and cysteine in the extracellu

111 Cysteamine hydrochloride (Cyst), 3-Mercaptopropionic aci

112 rd formulation (cysteamine [Cystaran]; 0.55% cysteamine hydrochloride + benzalkonium chloride 0.01%)

113 As a proof-of-concept, hydrophilic cysteamine hydrochloride as well as N-hexyl-4-mercaptobu

114 d directly using a specific radiolabel, [14C]cysteamine hydrochloride.

115 n situ quantitative estimation of endogenous cysteamine in brain tissue.

116 sed on layer-by-layer assembly was formed by cysteamine in combination with a fourth-generation poly(

117 relies upon the finding that hCBS will take cysteamine in place of L-homocysteine, thereby producing

118 It catalyzes oxidation of both cysteamine in sulfur metabolism and N-terminal cysteine-

119 itial barriers for selenocysteamine than for cysteamine in support of the experimental work.

120 Based on the formation rate of cysteamine in the OHSCs, we obtained the overall apparen

121 of N-acetylating a model compound containing cysteamine in the presence of acetyl-CoA, consistent wit

122 we investigate the reaction between HCN and cysteamine in water, which exhibits both sigmoidal react

123 eptide, and subsequent Michael addition with cysteamine increased masses by the predicated 77 and 154

124 Cysteamine-induced ulceration in EGF(-/-) mice was used

125 In fact, cysteamine is shown to be a potent activator of the enzy

126 eatest when combined with CFTR modulators or cysteamine, justifying further clinical testing of (R)-r

127 ng either a protein A sensor chip (SPR) or a cysteamine layer that modified the gold crystal (QCM-D)

128 bilayer and semi circled DDA on the MPA and cysteamine layers were confirmed by the increased redox

129 Plasma cysteamine levels showed diurnal variation, with peak le

130 cystamine also augmented basal intracellular cysteamine levels.

131 detection/quantification method that couples cysteamine-mediated HCHO scavenging with SPME GC-MS anal

132 opamine by the RNA aptamer, immobilized at a cysteamine-modified Au electrode, and further electroche

133 interactions between the positively charged cysteamine-modified electrode and the negatively charged

134 ence of 1,4-phenylene diisothiocyanate, on a cysteamine-modified gold electrode.

135 be performed by the RNA aptamer tethered to cysteamine-modified gold electrodes via the alkanethiol

136 gold electrodes via carbodiimide coupling to cysteamine-modified gold electrodes.

137 al bilayers was promoted by anchoring of the cysteamine moiety.

138 , heme oxygenase-1, neutrophil infiltration, cysteamine, mucin, hydrogen sulfide, ghrelin, adiponecti

139 e chain elongation intermediates as N-acetyl cysteamine (NAC) thioesters and have used them as substr

140 Copper-cysteamine nanoparticles are a new type of photosensitiz

141 is work confirms the effectiveness of copper-cysteamine nanoparticles as a photosensitizer when activ

142 pH-low insertion peptide-conjugated, copper-cysteamine nanoparticles in mouse tumors.

143 n this paper, we report on the use of copper-cysteamine nanoparticles, designed to be targeted to tum

144 se treatment with the cystine-depleting drug cysteamine only slows disease progression, there is an u

145 e synthesis of taurine, the final product of cysteamine oxidation and the second most abundant amino

146 obalt(II)- and nickel(II)-substituted ADO in cysteamine oxygenation.

147 ases remains less explored than the vanin-1 /cysteamine pathway.

148 ved when bronchial epithelia were exposed to cysteamine plus the antioxidant food supplement EGCG.

149 rophage cultures revealed that cystamine and cysteamine possess significant antiviral properties at n

150 with 70 mol % mercaptopropanol and 30 mol % cysteamine/propanedithiol to facilitate membrane fusion

151 Furthermore, treatment with cysteamine reduced alpha-smooth muscle actin-positive in

152 ults, treatment of cultured macrophages with cysteamine reduced cellular generation of reactive oxyge

153 rs (e.g., DMSO, glycerol, and cationic thiol cysteamine) reduces the incidence of instability after i

154 m and cystamine, diethyl dithiocarbamate and cysteamine, respectively, were found to be ineffective a

155 erestingly, exposure of cells to cysteine or cysteamine resulted in elevated intracellular hypotaurin

156 cystinotic cells' cystine content by use of cysteamine results in normalization of the apoptotic rat

157 peptides 2a-c and 3a-c to the reactive thiol cysteamine revealed that DeltaAla-containing peptides un

158 Specifically, conjugating cysteamine S-phosphate to the C-terminal of a self-assem

159 pecifically, Cu substrates are modified with cysteamine SAMs to uniformly anchor a Au(3+)-dimercaptos

160 SAuNPs@GO hybrid substrate (the test) and a cysteamine SAuNPs@GO substrate (the control).

161 lower BSA fouling compared with that of the cysteamine SAuNPs@GO substrate.

162 Overall, our studies confirm that cysteamine scavenging coupled to SPME GC-MS analysis pro

163 unosensor for the detection of MDM2 based on cysteamine self assembled monolayers on a clean polycrys

164 Compared to cystamine, cysteamine showed benefits in terms of crystal density s

165 using peptide carriers such as SIGCAFKILGY(-cysteamine) [SIGC(-cysteamine)].

166 The cystine-depleting agent cysteamine significantly delays symptoms, but it cannot

167 calls into question the autophagy modulator cysteamine, since no rescue of mutant CFTR function was

168 specificity for bioorthgonal short N-acetyl cysteamine (SNAc) donors.

169 ite-directed mutagenesis indicate that SIGC(-cysteamine) specifically and efficiently leads to cystea

170 e and the anti-oxidants allantoin, anserine, cysteamine, spermine, and squalene were amongst those on

171 od an aptamer was used to aggregate cationic cysteamine-stabilized CdTe/ZnS core/shell quantum dots,

172 Other antioxidants, approved for human use (cysteamine, succimer, dimercaprol), were not efficacious

173 utants in the presence of a concentration of cysteamine that elicits an intracluster open probability

174 of apoptosis that could be ameliorated with cysteamine, the human cystine depleting therapy.

175 Close therapeutic monitoring of cysteamine, the only available disease-modifying treatme

176 able analysis included delayed initiation of cysteamine therapy and higher mean leucocyte cystine lev

177 Oral cysteamine therapy delays disease progression by reducin

178 investigation into the potential benefit of cysteamine therapy in the treatment of CKD.

179 tment increased, and it decreased as time on cysteamine therapy increased.

180 In a study of renal ischemia reperfusion, cysteamine therapy initiated 10 days after injury and co

181 l therapeutic alternative in countries where cysteamine therapy is too expensive.

182 Long-term oral cysteamine therapy mitigates these effects.

183 de that serves as a chemical intermediate in cysteamine therapy of cystinosis, and PQLC2 gene silenci

184 adulthood and the effects of long-term oral cysteamine therapy on its nonrenal complications have no

185 patients with cystinosis who were receiving cysteamine therapy were recruited from three European re

186 who received long-term (> or =8 years) oral cysteamine therapy were taller and heavier, had a renal

187 ucidation of PQLC2 function may help improve cysteamine therapy.

188 eaction of some of its epoxide moieties with cysteamine to afford a monolith rich in surface thiol gr

189 hrough reaction of its epoxide moieties with cysteamine to afford a monolith rich in surface thiol gr

190 This method showed cysteamine to be a more efficient scavenger than the wid

191 g was captured by the electrode surface with cysteamine to detect the analyte, IL-6, after being atta

192 were synthesized by first covalently linking cysteamine to docosahexaenoic acid.

193 Early use of oral cysteamine to prevent cystine accumulation slows progres

194 In cysteamine-treated mice, fibrosis severity decreased sig

195 Cysteamine treatment ameliorates this phenotype, except

196 displayed more severe lesions in response to cysteamine treatment compared with wild-type counterpart

197 othyroidism, and death increased as time off cysteamine treatment increased, and it decreased as time

198 a group of patients who have periods without cysteamine treatment.

199 viously unrecognized antifibrotic actions of cysteamine via TGF-beta-independent mechanisms that incl

200 ne) decorated with gold nanoparticles-capped cysteamine was fabricated on the surface of gold electro

201 Vancomycin/synthetic acyl-N-acetyl cysteamine was not expected to be able to serve as a sur

202 phosphopantetheine, pantetheine, and finally cysteamine was observed with ThnR, ThnH, and ThnT, respe

203 onyl-S-pantetheine or L-threonyl-S-(N-acetyl)cysteamine was used as a small-molecule thioester analog

204 st successful of these biomimetic catalysts (cysteamine) was used to encapsulate firefly luciferase,

205 athione, and the simplest stable aminothiol, cysteamine, we enabled the nanoparticles to exhibit not

206 ead-space extraction SPME-GC-MS method using cysteamine, which provides similarly sensitive HCHO quan

207 nction was detected following treatment with cysteamine, while deleterious effects were observed when

208 s and randomized controlled trials comparing cysteamine with control or other formulations for treatm

209 2+/-0.2 mM for L-serine and 5.6+/-2.2 mM for cysteamine, with kcat = 1.3+/-0.1s(-1) for the formation

210 2.2+/-0.5 mM for L-serine and 6.6+/-2.2 for cysteamine, with kcat = 2.5+/-0.4 s(-1).